Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GlycoMimetics Inc GLYC

Healthcare Biotechnology
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of... see more

Recent & Breaking News (NDAQ:GLYC)

GlycoMimetics Appoints Seasoned Business Development Executive Armand Girard as New Vice President, Corporate Development

Business Wire April 23, 2014

GlycoMimetics Announces Presentation of Data on Rivipansel (GMI-1070) in Combination with Current FDA-Approved Treatment for Sickle Cell Disease

Business Wire April 14, 2014

GlycoMimetics, Inc. [GLYC] to Ring The NASDAQ Stock Market Closing Bell

GlobeNewswire April 10, 2014

GlycoMimetics Presents Data on Its E-Selectin Antagonist at American Association for Cancer Research Annual Meeting 2014

Business Wire April 9, 2014

GlycoMimetics Appoints Tim Pearson to Board of Directors and as Audit Committee Chair

Business Wire April 1, 2014

GlycoMimetics Reports Fourth Quarter and Year-End 2013 Results

Business Wire March 31, 2014

The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014

GlobeNewswire March 27, 2014

GlycoMimetics Announces Sudden Passing of Board Director and Audit Committee Member William Gust

Business Wire March 14, 2014

GlycoMimetics to Present at Barclays Global Healthcare Conference

Business Wire March 10, 2014

GlycoMimetics to Present GMI-1271 Research Findings at AACR Annual Meeting 2014

Business Wire March 5, 2014

Vista Partners Updates Coverage on Mast Therapeutics, Inc. (NYSE MKT: MSTX); Price Target $2.25

Marketwired February 28, 2014

RDInvesting Provides Investors with Free In-Depth Equity Reports on CJES, GLYC, HK and SLCA

Accesswire February 5, 2014

GlycoMimetics to Present at BIO CEO & Investor Conference

Business Wire February 3, 2014

GlycoMimetics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire January 15, 2014